Regeneron Pharmaceuticals (REGN) Earnings Date, Estimates & Call Transcripts → 348 million Americans lives to END as we know it? (From The Oxford Club) (Ad) Free REGN Stock Alerts $955.76 -14.21 (-1.46%) (As of 05/8/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateAug. 1EstimatedActual EPS (Feb. 2) $11.86 Beat By $1.13 Consensus EPS (Feb. 2) $10.73 Read Call TranscriptListen to Call Get Regeneron Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for REGN and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueREGN Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.REGN Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. Regeneron Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242$7.48$8.05$7.77Q2 20242$9.59$9.67$9.63Q3 20242$9.80$11.42$10.61Q4 20242$7.72$10.57$9.15FY 20248$34.59$39.71$37.15REGN Earnings Date and InformationRegeneron Pharmaceuticals last posted its quarterly earnings results on February 2nd, 2024. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping analysts' consensus estimates of $10.73 by $1.13. The business had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Its quarterly revenue was up .6% compared to the same quarter last year. Regeneron Pharmaceuticals has generated $33.85 earnings per share over the last year ($33.85 diluted earnings per share) and currently has a price-to-earnings ratio of 28.2. Earnings for Regeneron Pharmaceuticals are expected to grow by 4.04% in the coming year, from $38.86 to $40.43 per share. Regeneron Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 1st, 2024 based off prior year's report dates.Read More Regeneron Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/1/2024Estimated)------- 2/2/2024Q4 2023$10.73$11.86+$1.13$10.17$3.29 billion$3.43 billion 11/2/2023Q3 2023$9.39$10.17+$0.78$11.45$3.23 billion$3.36 billion 8/3/2023Q2 2023$8.48$10.24+$1.76$9.08$3.02 billion$3.16 billion 5/4/2023Q1 2023$7.71$8.44+$0.73$9.71$2.92 billion$3.16 billion2/3/2023Q4 2022$8.18$12.56+$4.38$11.42$3.11 billion$3.41 billion 11/3/2022Q3 2022$8.55$9.98+$1.43$8.30$2.79 billion$2.94 billion Get the Latest News and Ratings for REGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/3/2022Q2 2022$8.53$9.77+$1.24$12.07$2.80 billion$2.86 billion 5/4/2022Q1 2022$9.37$11.49+$2.12$14.37$2.69 billion$2.97 billion 2/4/2022Q4 2021$18.49$23.72+$5.23$27.75$4.49 billion$4.95 billion 11/4/2021Q3 2021$9.81$15.37+$5.56$16.41$2.80 billion$3.45 billion 8/5/2021Q2 2021$8.81$25.80+$16.99$27.97$3.90 billion$5.14 billion Regeneron Pharmaceuticals Earnings - Frequently Asked Questions When is Regeneron Pharmaceuticals's earnings date? Regeneron Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 1st, 2024 based off last year's report dates. Learn more on REGN's earnings history. Did Regeneron Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) reported $11.86 earnings per share (EPS) to beat the analysts' consensus estimate of $10.73 by $1.13. Learn more on analysts' earnings estimate vs. REGN's actual earnings. How can I listen to Regeneron Pharmaceuticals's earnings conference call? The conference call for Regeneron Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Regeneron Pharmaceuticals's conference call transcript? The conference call transcript for Regeneron Pharmaceuticals's latest earnings report can be read online. Read Transcript How much revenue does Regeneron Pharmaceuticals generate each year? Regeneron Pharmaceuticals (NASDAQ:REGN) has a recorded annual revenue of $13.10 billion. How much profit does Regeneron Pharmaceuticals generate each year? Regeneron Pharmaceuticals (NASDAQ:REGN) has a recorded net income of $3.95 billion. REGN has generated $33.85 earnings per share over the last four quarters. What is Regeneron Pharmaceuticals's price-to-earnings ratio? Regeneron Pharmaceuticals (NASDAQ:REGN) has a trailing price-to-earnings ratio of 28.24 and a forward price-to-earnings ratio of 24.59. The price/earnings-to-growth ratio is 2.74. What is Regeneron Pharmaceuticals's EPS forecast for next year? Regeneron Pharmaceuticals's earnings are expected to grow from $38.86 per share to $40.43 per share in the next year, which is a 4.04% increase. More Earnings Resources from MarketBeat Related Companies: VRTX Earnings GSK Earnings BMY Earnings SNY Earnings ZTS Earnings PFE Earnings TAK Earnings ABT Earnings RPRX Earnings BGNE Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Traders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future Outlook This page (NASDAQ:REGN) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithDems have chosen Biden replacement?Paradigm PressGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchObama’s Forever Term [exposed]Porter & CompanyPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.